CV drugs Flashcards Preview

cornelius 2 > CV drugs > Flashcards

Flashcards in CV drugs Deck (33)
Loading flashcards...
1
Q

phase 0 mediated by

A

fast sodium channels, cell depolarizes

2
Q

phase 1 mediated by

A

potassium channels open, cell begins to repolarize

3
Q

phase 2 mediated by

A

slow calcium channels open, potassium channels open

PLATEAU

4
Q

phase 3 mediated by

A

slow sodium channels close, potassium channels stay open and potassium rushes out, cell reporalizses quickly

5
Q

phase 4

A

resting membrane potential around -90

6
Q

pressure =

A

flow x resistance

7
Q

MAP =

A

CO x SVR

8
Q

CO =

A

HR x SV

9
Q

how to increase MAP

A

increase HR

increase SV

increase SVr

10
Q

alpha 1 location and action

A

vasculature, vasoconstrictions

11
Q

alpha 2 location and action

A

brain, sedation/sympathetic inhibition

12
Q

beta 1 location and action

A

heart, ionotropy/chronotropy/dromotropy

13
Q

beta 2 location and action

A

lung, bronchodilattion

14
Q

what group constitutes a catecholamine and increases beta and alpha activity

A

hydroxyl substition

15
Q

what do amine substitutions do

A

larger increases beta activity

16
Q

increasing side chain distance…

A

increases sympathomimetic activity

increases duration of action

17
Q

where is dopamine synthesized

A

kidney

18
Q

where does dopamine bind

A

a1, b1, D1

19
Q

low levels of dopamine bind

A

D1; increases renal flow

20
Q

moderate levels of dopamine bind

A

b1, increases BP and HR

21
Q

high levels of dopamine bind

A

a1, vasoconstriction

22
Q

where does norepinephrine bind

A

a1 mostly

23
Q

where does epi bind

A

non selective (a1, b1, b2)

24
Q

where does phenylephrine bind, what is its action, what is a risk

A

a1, vasoconstriction

increases preload and BP

risk: reflex brady

25
Q

where does ephedrine bind

A

a1, b1, b2

26
Q

ephedrine causes ____ because of _____

A

tachyphylaxis, NE depletion

27
Q

digoxin MOA

A

inhibits sodium potassium pump, increased intra cellular ca+

28
Q

new guidelines for stage 1 htn

A

130-139/80-89

29
Q

new guidelines for stage 2 htn

A

more than 140/more than 90

30
Q

three MOA for anti HTN drugs

A

effects on autonomic NS

inhibitor of RAAS

peripheral vasodilation

31
Q

dihydropyradines work where

A

vasculatur

32
Q

non-dihyrdopyradines work where

A

heart

33
Q

non selective beta blockers should not be used in

A

obstructive disease